LENZ Therapeutics, Inc. (LENZ) Form SCHEDULE 13D/A — Nov 2, 2026

$LENZForm SCHEDULE 13D/AFiled Nov 2, 2026, 5:45 PM ET0001346824-26-000251Original filing

RA Capital Management, Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund filed a Schedule 13D/A disclosing they ceased to be beneficial owners of more than 5% of LENZ Therapeutics common stock on October 29, 2026. The Reporting Persons sold approximately 4.0 million shares in open-market transactions on October 29, October 30, and November 2, 2026, at weighted average prices of $3.36, $3.27, and $2.98 respectively.

Key figures

Shares Outstanding: 31420343
Sale dates: ["2026-10-29","2026-10-30","2026-11-02"]
Sale price range low: 2.9
Sale price range high: 3.58
Remaining beneficial shares: 70533
Remaining ownership percent: 0.2%

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.